{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:47:17Z","timestamp":1790614037796,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02466-7","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T03:26:44Z","timestamp":1739590004000},"page":"1429-1437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study"],"prefix":"10.1007","volume":"62","author":[{"given":"Giovanni","family":"Petralli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Del","family":"Zoppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Moriconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Distaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia Rossana","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-8253","authenticated-orcid":false,"given":"Anna","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"2466_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"2466_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40842-020-00097-1","volume":"6","author":"S Tomah","year":"2020","unstructured":"Tomah S, Alkhouri N, Hamdy O (2020) Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand. Clin Diabetes Endocrinol 6:9. https:\/\/doi.org\/10.1186\/s40842-020-00097-1","journal-title":"Clin Diabetes Endocrinol"},{"key":"2466_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M (2021) The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 18:599\u2013612. https:\/\/doi.org\/10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2466_CR4","doi-asserted-by":"publisher","first-page":"110699","DOI":"10.1016\/j.diabres.2023.110699","volume":"200","author":"Y Gao","year":"2023","unstructured":"Gao Y, Zhao T, Song S, Duo Y, Gao J, Yuan T et al (2023) Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a literature review and meta-analysis. Diabetes Res Clin Pract 200:110699. https:\/\/doi.org\/10.1016\/j.diabres.2023.110699","journal-title":"Diabetes Res Clin Pract"},{"key":"2466_CR5","doi-asserted-by":"publisher","first-page":"e00112","DOI":"10.1002\/edm2.112","volume":"3","author":"MV Chakravarthy","year":"2020","unstructured":"Chakravarthy MV, Neuschwander-Tetri BA (2020) The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 3:e00112. https:\/\/doi.org\/10.1002\/edm2.112","journal-title":"Endocrinol Diabetes Metab"},{"key":"2466_CR6","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H (2023) Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res 119:1787\u20131798. https:\/\/doi.org\/10.1093\/cvr\/cvad095","journal-title":"Cardiovasc Res"},{"key":"2466_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40292-023-00611-3","volume":"30","author":"TF Roohi","year":"2023","unstructured":"Roohi TF, Faizan S, Parray ZA, Baig MDAI, Mehdi S, Kinattingal N et al (2023) Beyond glucose: the dual assault of oxidative and ER stress in Diabetic disorders. High Blood Press Cardiovasc Prev 30:513\u2013531. https:\/\/doi.org\/10.1007\/s40292-023-00611-3","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2466_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1210\/jc.2017-02343","volume":"103","author":"P Dandona","year":"2018","unstructured":"Dandona P, Ghanim H, Abuaysheh S, Green K, Dhindsa S, Makdissi A et al (2018) Exenatide increases IL-1RA concentration and induces Nrf-2\u2013Keap-1\u2013Regulated antioxidant enzymes: relevance to \u03b2-Cell function. J Clin Endocrinol Metab 103:1180\u20131187. https:\/\/doi.org\/10.1210\/jc.2017-02343","journal-title":"J Clin Endocrinol Metab"},{"key":"2466_CR9","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1038\/s41598-021-90191-w","volume":"11","author":"S Sivalingam","year":"2021","unstructured":"Sivalingam S, Larsen EL, van Raalte DH, Muskiet MHA, Smits MM, Tonneijck L et al (2021) The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Sci Rep 11:10624. https:\/\/doi.org\/10.1038\/s41598-021-90191-w","journal-title":"Sci Rep"},{"key":"2466_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-020-01106-4","volume":"9","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol 9:156. https:\/\/doi.org\/10.1186\/s12933-020-01106-4","journal-title":"Cardiovasc Diabetol"},{"key":"2466_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, STEP 5 Study Group et al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28:2083\u20132091. https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"2466_CR12","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.3390\/ijms24108494","volume":"24","author":"JA Inia","year":"2023","unstructured":"Inia JA, Stokman G, Morrison MC, Worms N, Verschuren L, Caspers MPM et al (2023) Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr-\/- Leiden mice. Int J Mol Sci 24:8494. https:\/\/doi.org\/10.3390\/ijms24108494","journal-title":"Int J Mol Sci"},{"key":"2466_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, NN9931-4296 Investigators et al (2021) A Placebo- Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"2466_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, NN9931-4492 investigators et al (2023) Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8:511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2466_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13300-023-01493-3","volume":"15","author":"T Omachi","year":"2024","unstructured":"Omachi T, Ohara M, Fujikawa T, Kohata Y, Sugita H, Irie S et al (2024) Comparison of effects of Injectable Semaglutide and Dulaglutide on oxidative stress and glucose variability in patients with type 2 diabetes Mellitus: a prospective preliminary study. Diabetes Ther 15:111\u2013126. https:\/\/doi.org\/10.1007\/s13300-023-01493-3","journal-title":"Diabetes Ther"},{"key":"2466_CR16","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"ESC Scientific Document Group","year":"2021","unstructured":"ESC Scientific Document Group (2021) ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021 42:3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J 2021"},{"key":"2466_CR17","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1210\/clinem\/dgaa757","volume":"106","author":"J Suvan","year":"2021","unstructured":"Suvan J, Masi S, Harrington Z, Santini E, Raggi F, D\u2019Aiuto F et al (2021) Effect of treatment of Periodontitis on Incretin Axis in obese and nonobese individuals: a Cohort Study. J Clin Endocrinol Metab 106:e74\u2013e82. https:\/\/doi.org\/10.1210\/clinem\/dgaa757","journal-title":"J Clin Endocrinol Metab"},{"key":"2466_CR18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J (2017) Effect of oral Semaglutide compared with placebo and Subcutaneous Semaglutide on Glycemic Control in patients with type 2 diabetes: a Randomized Clinical Trial. JAMA 318:1460\u20131470. https:\/\/doi.org\/10.1001\/jama.2017.14752","journal-title":"JAMA"},{"key":"2466_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/diabetology5010005","volume":"5","author":"S Klobu\u010dar","year":"2024","unstructured":"Klobu\u010dar S, Belan\u010di\u0107 A, Buk\u0161a I, Mori\u0107 N, Raheli\u0107 D (2024) Effectiveness of oral versus injectable semaglutide in adults with type 2 diabetes: results from a Retrospective Observational Study in Croatia. Diabetology 5:60\u201368. https:\/\/doi.org\/10.3390\/diabetology5010005","journal-title":"Diabetology"},{"key":"2466_CR20","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1111\/dom.15554","volume":"26","author":"GP Fadini","year":"2024","unstructured":"Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A (2024) GLIMPLES study investigators. Oral or injectable semaglutide for the management of type 2 diabetes in routine care: a multicentre observational study comparing matched cohorts. Diabetes Obes Metab 26:2390\u20132400. https:\/\/doi.org\/10.1111\/dom.15554","journal-title":"Diabetes Obes Metab"},{"key":"2466_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R et al (2014) Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 64:731\u2013737. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03062","journal-title":"Hypertension"},{"key":"2466_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/dme.13769","volume":"35","author":"F Gomez-Peralta","year":"2018","unstructured":"Gomez-Peralta F, Lecube A, Fern\u00e1ndez-Mari\u00f1o A, Alonso Troncoso I, Morales C, Morales-P\u00e9rez FM et al (2018) Interindividual differences in the clinical effectiveness of liraglutide in type 2 diabetes: a real-world retrospective study conducted in Spain. Diabet Med 35:1605\u20131612. https:\/\/doi.org\/10.1111\/dme.13769","journal-title":"Diabet Med"},{"key":"2466_CR23","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.conctc.2022.100944","volume":"28","author":"Y Alhindi","year":"2022","unstructured":"Alhindi Y, Avery A (2022) The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis. Contemp Clin Trials Commun 28:100944. https:\/\/doi.org\/10.1016\/j.conctc.2022.100944","journal-title":"Contemp Clin Trials Commun"},{"key":"2466_CR24","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/nu14214673","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D et al (2022) Once-Weekly Subcutaneous Semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-Week prospective real-life study. Nutrients 14:4673. https:\/\/doi.org\/10.3390\/nu14214673","journal-title":"Nutrients"},{"key":"2466_CR25","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/pharmaceutics15082163","volume":"15","author":"H Nomoto","year":"2023","unstructured":"Nomoto H, Takahashi Y, Takano Y, Yokoyama H, Tsuchida K, Nagai S et al (2023) Effect of switching to once-weekly semaglutide on non-alcoholic fatty liver disease: the SWITCH-SEMA 1 Subanalysis. Pharmaceutics 15:2163. https:\/\/doi.org\/10.3390\/pharmaceutics15082163","journal-title":"Pharmaceutics"},{"key":"2466_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jgh3.12780","volume":"6","author":"T Arai","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A, Ono H, Kawano T, Yoshida Y et al (2022) Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: a pilot study. JGH Open 6:503\u2013511. https:\/\/doi.org\/10.1002\/jgh3.12780","journal-title":"JGH Open"},{"key":"2466_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367\u2013378.e5; quiz e14-5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"2466_CR28","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R et al (2021) Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology 74:1220\u20131233. https:\/\/doi.org\/10.1002\/hep.31806","journal-title":"Hepatology"},{"key":"2466_CR29","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.3390\/ijms25052961","volume":"25","author":"M Soto-Catal\u00e1n","year":"2024","unstructured":"Soto-Catal\u00e1n M, Opazo-R\u00edos L, Quiceno H, L\u00e1zaro I, Moreno JA, G\u00f3mez-Guerrero C et al (2024) Semaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2- diabetic mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci 25:2961. https:\/\/doi.org\/10.3390\/ijms25052961","journal-title":"Int J Mol Sci"},{"key":"2466_CR30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/biomedicines11051362","volume":"11","author":"AM Patti","year":"2023","unstructured":"Patti AM, Giglio RV, Allotta A, Bruno A, Di Bella T, Pantea Stoian A et al (2023) Effect of Semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes. Biomedicines 11:1362. https:\/\/doi.org\/10.3390\/biomedicines11051362","journal-title":"Biomedicines"},{"key":"2466_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s13300-024-01551-4","volume":"15","author":"S Roy Chowdhury","year":"2024","unstructured":"Roy Chowdhury S, Sadouki F, Collins E, Keen F, Bhagi R, Lim YSJ et al (2024) Real-world use of oral and subcutaneous semaglutide in routine clinical practice in the UK: a single-centre, retrospective observational study. Diabetes Ther 15:869\u2013881. https:\/\/doi.org\/10.1007\/s13300-024-01551-4","journal-title":"Diabetes Ther"},{"key":"2466_CR32","doi-asserted-by":"publisher","first-page":"212585","DOI":"10.7573\/dic.212585","volume":"8","author":"ME R\u00f8der","year":"2019","unstructured":"R\u00f8der ME (2019) Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs Context 8:212585. https:\/\/doi.org\/10.7573\/dic.212585","journal-title":"Drugs Context"},{"key":"2466_CR33","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s11010-023-04784-2","volume":"479","author":"X Pan","year":"2024","unstructured":"Pan X, Yang L, Wang S, Liu Y, Yue L, Chen S (2024) Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression. Mol Cell Biochem 479:1133\u20131147. https:\/\/doi.org\/10.1007\/s11010-023-04784-2","journal-title":"Mol Cell Biochem"},{"key":"2466_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2022.03.032","volume":"352","author":"JK Jensen","year":"2022","unstructured":"Jensen JK, Binderup T, Grandjean CE, Bentsen S, Ripa RS, Kjaer A (2022) Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis 352:88\u201395. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.03.032","journal-title":"Atherosclerosis"},{"key":"2466_CR35","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/ijms25031854","volume":"25","author":"M Hachu\u0142a","year":"2024","unstructured":"Hachu\u0142a M, Kosowski M, Ryl S, Basiak M, Okopie\u0144 B (2024) Impact of Glucagon-Like peptide 1 receptor agonists on biochemical markers of the initiation of atherosclerotic process. Int J Mol Sci 25:1854. https:\/\/doi.org\/10.3390\/ijms25031854","journal-title":"Int J Mol Sci"},{"key":"2466_CR36","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.3390\/ijms24065714","volume":"24","author":"I Reppo","year":"2023","unstructured":"Reppo I, Jakobson M, Volke V (2023) Effects of Semaglutide and Empagliflozin on inflammatory markers in patients with type 2 diabetes. Int J Mol Sci 24:5714. https:\/\/doi.org\/10.3390\/ijms24065714","journal-title":"Int J Mol Sci"},{"key":"2466_CR37","doi-asserted-by":"publisher","first-page":"204201882312073","DOI":"10.1177\/20420188231207348","volume":"14","author":"S Rella","year":"2023","unstructured":"Rella S, Onyiah J, Baker C, Singh V, Her A, Rasouli N (2023) Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus. Ther Adv Endocrinol Metab 14:20420188231207348. https:\/\/doi.org\/10.1177\/20420188231207348","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2466_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13098-024-01344-6","volume":"16","author":"G Petralli","year":"2024","unstructured":"Petralli G, Raggi F, Del Zoppo A, Rovera C, Salvati A, Brunetto MR et al (2024) Response to semaglutide of non-drinker subjects with type 2 diabetes. Diabetol Metab Syndr 16:103. https:\/\/doi.org\/10.1186\/s13098-024-01344-6","journal-title":"Diabetol Metab Syndr"},{"key":"2466_CR39","doi-asserted-by":"publisher","first-page":"971745","DOI":"10.3389\/fendo.2022.971745","volume":"13","author":"E Somm","year":"2022","unstructured":"Somm E, Jornayvaz FR (2022) Interleukin-18 in metabolism: from mice physiology to human diseases. Front Endocrinol (Lausanne) 13:971745. https:\/\/doi.org\/10.3389\/fendo.2022.971745","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2466_CR40","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3390\/antiox10091379","volume":"10","author":"V Lambadiari","year":"2021","unstructured":"Lambadiari V, Thymis J, Kouretas D, Skaperda Z, Tekos F, Kousathana F et al (2021) Effects of a 12- month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes. Antioxid (Basel) 10:1379. https:\/\/doi.org\/10.3390\/antiox10091379","journal-title":"Antioxid (Basel)"}],"updated-by":[{"DOI":"10.1007\/s00592-025-02482-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000}}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02466-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:05:18Z","timestamp":1757952318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02466-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2466"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02466-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00592-025-02482-7","asserted-by":"object"}]},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00592-025-02482-7","URL":"https:\/\/doi.org\/10.1007\/s00592-025-02482-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest related to the present manuscript. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}